Jubilant Pharmova. has filed a patent for a process to prepare a highly concentrated allergenic intermediate from a dilute allergen extract. The method involves concentrating a crude extract using pervaporation, adjusting pH, treating with a ketonic solvent, and recovering the precipitate through filtration. GlobalData’s report on Jubilant Pharmova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jubilant Pharmova, Graphene oxide composites was a key innovation area identified from patents. Jubilant Pharmova's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Process for preparing highly concentrated allergenic intermediate from dilute extract
A patent application (Publication Number: US20240010675A1) describes a process for preparing a highly concentrated allergenic intermediate from a dilute allergen extract. The process involves concentrating a crude extract using pervaporation, adjusting the pH, treating with a ketonic solvent to form a precipitate, and recovering the precipitate through filtration to obtain the desired allergenic intermediate. The allergenic source material can include various allergens such as house dust mite, insect, venom, animal hair, dander, and food allergens. The extraction process, carried out at specific temperature ranges and concentration ratios, separates the biological material into solid and liquid phases to obtain the crude extract.
Furthermore, the patent application includes details about a kit for compounding the allergenic intermediate, comprising lyophilized allergenic intermediate, a liquid diluent, and instructions for preparation and use. The kit allows for the combination of contents from two containers to achieve a specific concentration of allergenic extract. The liquid diluent in the kit includes specific components like glycerol-cocas fluid with sodium chloride, sodium bicarbonate, glycerin, and water for injection. Additionally, the patent application outlines a method for diagnosing cat allergy in individuals using the kit through a skin prick method. The method's clinical parameters, including sensitivity, specificity, negative predictive value, and positive predictive value, ensure accurate diagnosis with high sensitivity and specificity levels in populations with varying cat allergy prevalence rates.
To know more about GlobalData’s detailed insights on Jubilant Pharmova, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
